BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22193290)

  • 21. Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.
    He JP; Hao Y; Li M; Wang J; Guo FJ
    Orthop Surg; 2014 May; 6(2):145-53. PubMed ID: 24890297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
    Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
    J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VEGF expression as a prognostic marker in osteosarcoma.
    Bajpai J; Sharma M; Sreenivas V; Kumar R; Gamnagatti S; Khan SA; Rastogi S; Malhotra A; Bakhshi S
    Pediatr Blood Cancer; 2009 Dec; 53(6):1035-9. PubMed ID: 19621435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.
    Chang KJ; Kong CB; Cho WH; Jeon DG; Lee SY; Lim I; Lim SM
    Skeletal Radiol; 2015 Apr; 44(4):529-37. PubMed ID: 25431093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
    Raciborska A; Bilska K; Drabko K; Michalak E; Chaber R; Pogorzała M; Połczyńska K; Sobol G; Wieczorek M; Muszyńska-Rosłan K; Rychlowska-Pruszyńska M; Rodriguez-Galindo C; Dziuk M
    Clin Transl Oncol; 2016 Feb; 18(2):189-95. PubMed ID: 26250765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of multi-parametric magnetic resonance imaging combined with machine learning in the assessment of necrosis of osteosarcoma after neoadjuvant chemotherapy: a preliminary study.
    Huang B; Wang J; Sun M; Chen X; Xu D; Li ZP; Ma J; Feng ST; Gao Z
    BMC Cancer; 2020 Apr; 20(1):322. PubMed ID: 32293344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different
    El-Hennawy G; Moustafa H; Omar W; Elkinaai N; Kamel A; Zaki I; Farid N; El-Kholy E
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28605. PubMed ID: 32706520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can pretreatment
    Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
    Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis.
    Bajpai J; Gamnagatti S; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Safaya R; Bakhshi S
    Pediatr Radiol; 2011 Apr; 41(4):441-50. PubMed ID: 20978754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities.
    Byun BH; Kong CB; Park J; Seo Y; Lim I; Choi CW; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Oct; 54(10):1725-32. PubMed ID: 23949909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
    Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T1 mapping as a surrogate marker of chemotherapy response evaluation in patients with osteosarcoma.
    Baidya Kayal E; Sharma N; Sharma R; Bakhshi S; Kandasamy D; Mehndiratta A
    Eur J Radiol; 2022 Mar; 148():110170. PubMed ID: 35086004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma.
    Costelloe CM; Macapinlac HA; Madewell JE; Fitzgerald NE; Mawlawi OR; Rohren EM; Raymond AK; Lewis VO; Anderson PM; Bassett RL; Harrell RK; Marom EM
    J Nucl Med; 2009 Mar; 50(3):340-7. PubMed ID: 19258257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.
    Casey DL; Wexler LH; Fox JJ; Dharmarajan KV; Schoder H; Price AN; Wolden SL
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1136-42. PubMed ID: 25539372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
    Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
    J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.